Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 6

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 15
Chunk 6
---
40431 
     
    March 7, 2022 

    10.1^
     
    Form of Indemnification Agreement with directors and officers
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.2^
     
    Form of Change in Control and Severance Agreement
     
    10-K
     
     001-40431
     
    March 7, 2022 

    10.3^
     
    2021 Equity Incentive Plan and forms of award agreements
     
    S-8
     
    333-276372
     
    January 4, 2024

128

    10.4^
     
    2021 Employee Stock Purchase Plan and forms of award agreements
     
    S-8
     
    333-276372
     
    January 4, 2024

    10.5^
     
    2022 Equity Inducement Plan and forms of agreement
     
    S-8
     
    333-268071
     
    October 31, 2022

    10.6†
     
    Office Lease, dated June 26, 2024, by and between Arcus Biosciences, Inc., a Delaware corporation, and Day One Biopharmaceuticals, Inc.

    X 

    10.7†
     
    Asset Transfer and License Agreement, effective as of December 16, 2019, by and between DOT Therapeutics-1, Inc. and Millennium Pharmaceuticals, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.8†
     
    License Agreement for RAF, effective as of December 16, 2019, by and between Sunesis Pharmaceuticals, Inc. and DOT Therapeutics-1, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.9†
     
    License Agreement, dated February 10, 2021, by and between Merck KGaA, Darmstadt, Germany and Day One Biopharmaceuticals, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.10
     
    Stock Exchange Agreement, dated May